Most patients, and even some providers, get the comparison between collagen induction therapy (CIT) and laser resurfacing wrong.
From the outside, it looks like a simple choice: needles (microneedling) vs. light (fractional lasers like Fraxel). The reality is more nuanced. The right choice depends less on the technology itself and more on the patient's skin type, downtime tolerance, and specific concern. In my role coordinating treatment plans at a clinic that's used both Solta Medical's Fraxel and various microneedling platforms for over 200 procedures, I've seen this firsthand. The biggest mistake is treating them as direct competitors. They're not. They're different tools.
Let me be direct: if you're chasing maximal results for deep acne scars or significant photoaging, and you can tolerate a few days of social downtime, Fraxel Restore Dual is your gold standard. If you want solid improvement with almost zero downtime, or if you have darker skin (Fitzpatrick IV-VI), collagen induction therapy is often the safer, smarter bet. The marketing tries to frame it as 'new vs. old,' but that's a distraction.
The Core Distinction: Why Depth Matters
Here's the key technical difference that explains almost everything else. Fraxel creates microscopic columns of thermal injury deep in the dermis. That's the 'fractional' part—it leaves surrounding tissue intact for rapid healing. This stimulates a powerful, deep collagen remodeling response. Collagen induction therapy, using fine needles, creates mechanical injury. It also stimulates collagen, but primarily in the superficial to mid-dermis. In March 2024, our clinic had a patient who'd done six CIT sessions for moderate acne scarring. Results were OK, but not great. A single Fraxel treatment, 36 hours before a big event she'd planned around, gave her noticeably better improvement. The trade-off was three days of visible redness and swelling she had to schedule for.
People assume the newest modality is always the best. What they don't see is that the 'newness' of microneedling has made it a massive marketing success, but the clinical data for deep textural change still favors fractional photothermolysis. The 'always get microneedling' advice ignores the fact that for deep, pitted scars, you need to go deeper than most microneedling devices can safely reach without significant risk.
What the Marketing Doesn't Tell You About Fraxel
Fraxel gets a reputation—sometimes unfairly—for being painful and for requiring 'downtime.' Let's break that down. Is it uncomfortable? During the treatment, yes. We use topical anesthetic, and it's manageable. The sensation is often described as a hot prickling, not excruciating pain. What's more important for planning is the post-treatment phase. For 24-48 hours, the skin looks and feels like a moderate sunburn. Then it bronzes and peels for another 2-3 days. You can work from home, but you won't want to be in a client-facing role. The upside is that for conditions like Fraxel is specifically FDA-cleared for—periorbital wrinkles, dyschromia, non-scalloped acne scars—the results are demonstrably superior in my experience. Based on our internal data from 200+ Fraxel treatments, we see an average of 60-70% improvement in fine lines and pigmentation after a single treatment plan, and often closer to 80-85% for textural issues like acne scarring after a series of 3.
In my first year, I made the classic rookie mistake: assumed all laser treatments were high-risk for darker skin types. That's true for some older, ablative lasers. For non-ablative fractional lasers like Fraxel Restore Dual, which has a 1550nm wavelength, the risk of hyperpigmentation is much lower—but it's not zero. I learned that lesson the hard way when we treated a Fitzpatrick IV patient without proper pre-treatment prep, and she developed transient post-inflammatory hyperpigmentation that took three months to resolve.
The Case for Collagen Induction Therapy
CIT's killer app is convenience and safety. It's tempting to think you just poke holes in the skin and collagen grows. But the protocol is critical for results. The depth of the needles, the number of passes, and importantly, what you're applying topically (if anything) during treatment makes a huge difference. Done well, with proper technique and a device like a SkinPen, it's excellent for superficial texture, pore size, and skin laxity. The upside was minimal downtime—redness for 12-24 hours. The risk was that for deep wrinkles or scars, the improvement might be underwhelming. I kept asking myself: is the convenience worth potentially disappointing the patient?
Calculated the worst case: the patient is happy because recovery was easy, but the results are 'meh.' Best case: solid improvement with no social downtime. The expected value said it's a great option for the right patient, but the downside felt like we'd lose their trust if they expected Fraxel-level results.
Here's what you need to know: CIT is often recommended as a first-line treatment for skin rejuvenation in patients with darker skin types (Fitzpatrick III-VI) precisely because the risk of pigmentation changes is so low. For patients who want a 'lunchtime procedure' and will accept gradual, meaningful improvement over a series of 3-6 treatments, it's an excellent choice. It's also significantly less expensive per session.
So, Which One Do You Choose?
Here's the practical decision tree I've landed on after hundreds of consults:
- Choose Fraxel (or another fractional laser) if: You have significant textural concerns (deep acne scars, surgical scars, defined wrinkles), moderate to severe photoaging, or you can handle 4-5 days of social downtime. You want maximal improvement in a single session or a short series of 3-5 treatments.
- Choose Collagen Induction Therapy if: You have mild to moderate skin texture concerns, enlarged pores, superficial fine lines, and you want minimal downtime. Or, if you have a darker skin type (IV-VI) and want to minimize the risk of unwanted pigmentation changes. It's also a fantastic maintenance treatment after a laser series to continue building collagen.
What most online articles don't tell you: the combination approach is often the most powerful. A protocol of 1-2 Fraxel treatments to create deep structural change, followed by a series of CIT treatments to build surface quality and maintain the results, is a strategy we've used with excellent outcomes for over 40 patients in the last two years alone. It's not cheap—count on $1,500-3,000 for a laser series and $1,000-2,000 for a CIT series—but the cumulative effect exceeds either modality used alone.
The Bottom Line: It's About the Patient, Not the Technology
Industry-standard print resolution for a medical brochure is 300 DPI. That's a fact. The 'resolution' for choosing a skin rejuvenation treatment isn't a one-number answer. It's a patient-by-patient decision. The technology that's best on paper—Fraxel for collagen induction—isn't always the best in practice. What was best practice in 2020 (often treating everyone with a single modality) may not apply in 2025. The fundamentals haven't changed: deeper injury drives more remodeling, which requires more downtime and carries more risk. But the execution—combining modalities, using improved protocols, managing expectations—has transformed.
That said, I should note a crucial boundary: this advice applies to treating the face and neck. For other body areas with different healing characteristics, and for conditions like hypertrophic scars or stretch marks, the calculus shifts again. A deep, fractional laser is often the only option that produces meaningful improvement. A CIT approach on stretch marks, for example, frequently disappoints. As always, a consultation with a qualified provider who understands both technologies is your best first step.
We've focused on Solta Medical's Fraxel Restore Dual as the laser example because it's the most studied and widely available fractional laser on the market. Other devices from Cynosure or Cutera are worth evaluating on their own merits, but the core principles outlined here—depth, healing, risk profile—remain the same. Don't let the marketing confuse the underlying science.
